Today Charles River Laboratories International In (CRL) Hits New Lifetime High
Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.
Trade-Ideas LLC identified
Charles River Laboratories International In
(
) as a new lifetime high candidate. In addition to specific proprietary factors, Trade-Ideas identified Charles River Laboratories International In as such a stock due to the following factors:
- CRL has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $42.2 million.
- CRL has traded 67,478 shares today.
- CRL is trading at a new lifetime high.
EXCLUSIVE OFFER: Get the inside scoop on opportunities in CRL with the Ticky from Trade-Ideas. See the FREE profile for CRL NOW at Trade-Ideas
More details on CRL:
Charles River Laboratories International, Inc., an early-stage contract research company, provides drug discovery and preclinical development services worldwide. CRL has a PE ratio of 30.3. Currently there are 6 analysts that rate Charles River Laboratories International In a buy, no analysts rate it a sell, and 10 rate it a hold.
The average volume for Charles River Laboratories International In has been 427,100 shares per day over the past 30 days. Charles River Laboratories International In has a market cap of $3.9 billion and is part of the health care sector and health services industry. The stock has a beta of 0.94 and a short float of 2.8% with 2.70 days to cover. Shares are up 28.8% year-to-date as of the close of trading on Wednesday.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.
Analysis:
rates Charles River Laboratories International In as a
. The company's strengths can be seen in multiple areas, such as its solid stock price performance, impressive record of earnings per share growth, compelling growth in net income, revenue growth and notable return on equity. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated.
Highlights from the ratings report include:
- Powered by its strong earnings growth of 47.50% and other important driving factors, this stock has surged by 33.08% over the past year, outperforming the rise in the S&P 500 Index during the same period. Regarding the stock's future course, although almost any stock can fall in a broad market decline, CRL should continue to move higher despite the fact that it has already enjoyed a very nice gain in the past year.
- CHARLES RIVER LABS INTL INC has improved earnings per share by 47.5% in the most recent quarter compared to the same quarter a year ago. The company has demonstrated a pattern of positive earnings per share growth over the past two years. We feel that this trend should continue. During the past fiscal year, CHARLES RIVER LABS INTL INC increased its bottom line by earning $2.69 versus $2.15 in the prior year. This year, the market expects an improvement in earnings ($3.60 versus $2.69).
- The net income growth from the same quarter one year ago has greatly exceeded that of the S&P 500, but is less than that of the Life Sciences Tools & Services industry average. The net income increased by 42.2% when compared to the same quarter one year prior, rising from $19.10 million to $27.17 million.
- Despite its growing revenue, the company underperformed as compared with the industry average of 16.6%. Since the same quarter one year prior, revenues rose by 13.9%. Growth in the company's revenue appears to have helped boost the earnings per share.
- The return on equity has improved slightly when compared to the same quarter one year prior. This can be construed as a modest strength in the organization. Compared to other companies in the Life Sciences Tools & Services industry and the overall market, CHARLES RIVER LABS INTL INC's return on equity exceeds that of both the industry average and the S&P 500.
- You can view the full Charles River Laboratories International In Ratings Report.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.
null